Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Melanoma × Metformin × Clear all

Phase

Status

Recruiting 3 Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 5 Polycystic Ovary Syndrome 4 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Insulin Resistance 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Sarcoma, Myeloid 1 Racism 1 Ovarian Neoplasms 1 Neoplasms 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Infertility 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Colorectum 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Brain Neoplasms 1 Anovulation 1

Interventions

Nivolumab 15 Ipilimumab 13 pembrolizumab 8 trametinib 7 Cyclophosphamide 7 dabrafenib 6 Radiotherapy 5 Interleukin-2 5 sargramostim 4 aldesleukin 4 Vemurafenib 4 130-nm albumin-bound paclitaxel 4 Specimen Handling 3 Radiosurgery 3 Melphalan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 fludarabine 2 encorafenib 2 binimetinib 2 Magnetic Resonance Spectroscopy 2 Introns 2 Infliximab 2 CTLA-4 Antigen 2 Biopsy 2 Bevacizumab 2 Albumin-Bound Paclitaxel 2 yeast-CEA vaccine 1 vitespin 1 vedolizumab 1 urelumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

University of Louisville

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡